SILO - Psyched: Psychedelics For Brain Injury Kentucky Initiative Stalled DEA Quotas Insurance Codes $50M For Atai And More | Benzinga
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Results of a first-in-class clinical trial on ibogaine-magnesium therapy for Special Operations Veterans (SOV) with repeated blast exposure have been published in the journal Nature. Although preliminary, outcomes have long been awaited as they provide evidence of ibogaine’s neuro-restorative effects.
Led by Stanford University’s Brain Stimulation Lab director Dr. Nolan Williams, the study is the first prospective clinician-rated ibogaine trial as compared to prior published studies on ibogaine, with results based on self-reports. Keep reading HERE.
Kentucky's Promising Opioid Addiction Treatment Initiative Stalls As New AG Ousts Leading Advocate
Once a promising pioneer state in ibogaine research for the treatment of opioid use disorder, Kentucky’s appointment of Attorney General Russell Coleman has brought about the removal of Bryan Hubbard.
As chair and executive director of the Kentucky Opioid Abatement Advisory Commission (KYOAAC), Hubbard led the proposal to use 5% (or $42 million) of the $900 million from the state’s opioid settlements to fund the ibogaine studies. Keep reading HERE.
DEA Raises THC, Psilocybin And DMT Production Quotas For Scientific Research Purposes
The DEA is proposing the production of higher amounts of THC, psilocybin and DMR for research in 2024. In a notice scheduled to be published in the Federal Register on Wednesday, the agency said it is raising the proposed amounts as a response to a request from registered producers, writes Marijuana Moment.
This shows a continuous trend, as ...